Key result
CRISPR-Cas9 genome editing represents a promising approach for targeted immunomodulation in autoimmune diseases, though few studies on its treatment application have been reported so far.
Why the study?
Gene therapy using CRISPR-Cas9 is a promising approach, but few studies on the treatment of autoimmune diseases using CRISPR-Cas9 have been reported so far.
What are the potential target genes for immunomodulation using CRISPR-Cas9 in autoimmune diseases?
What are the potential target genes for immunomodulation using CRISPR-Cas9 in autoimmune diseases?
CRISPR-Cas9 genome editing holds potential for tailored immunomodulation in autoimmune diseases by targeting specific genes.
Autoimmune diseases are disorders that destruct or disrupt the body's own tissues by its own immune system. Several studies have revealed that polymorphisms of multiple genes are involved in autoimmune diseases. Meanwhile, gene therapy has become a promising approach in autoimmune diseases, and clustered regularly interspaced palindromic repeats and CRISPR-associated protein 9 (CRISPR-Cas9) has become one of the most prominent methods. It has been shown that CRISPR-Cas9 can be applied to knock out proprotein convertase subtilisin/kexin type 9 (PCSK9) or block PCSK9, resulting in lowering low-density lipoprotein cholesterol. In other studies, it can be used to treat rare diseases such as ornithine transcarbamylase (OTC) deficiency and hereditary tyrosinemia. However, few studies on the treatment of autoimmune disease using CRISPR-Cas9 have been reported so far. In this review, we highlight the current and potential use of CRISPR-Cas9 in the management of autoimmune diseases. We summarize the potential target genes for immunomodulation using CRISPR-Cas9 in autoimmune diseases including rheumatoid arthritis (RA), inflammatory bowel diseases (IBD), systemic lupus erythematosus (SLE), multiple sclerosis (MS), type 1 diabetes mellitus (DM), psoriasis, and type 1 coeliac disease. This article will give a new perspective on understanding the use of CRISPR-Cas9 in autoimmune diseases not only through animal models but also in human models. Emerging approaches to investigate the potential target genes for CRISPR-Cas9 treatment may be promising for the tailored immunomodulation of some autoimmune diseases in the near future.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2022) conducted a review in Autoimmune diseases. CRISPR-Cas9 was evaluated. CRISPR-Cas9 genome editing represents a promising approach for targeted immunomodulation in autoimmune diseases, though few studies on its treatment application have been reported so far.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: